Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether treatment with an experimental drug called
YF476 in patients with Barrett's esophagus reduces the expression of tissue markers that are
associated with an increased risk of developing esophageal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Julian A Abrams, MD
Collaborators:
National Institute for Health Research, United Kingdom Trio Medicines Ltd.